Adcytherix
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $105M
Overview
Developing innovative antibody therapies targeting oncology through immune modulation or direct inhibition.
Oncology
Technology Platform
An antibody discovery and engineering platform aimed at generating novel therapeutics with optimized properties for oncology targets.
Funding History
1Total raised:$105M
PIPE$105M
Opportunities
Potential to develop a best-in-class or first-in-class antibody that could attract partnership deals with larger oncology-focused companies.
Risk Factors
High risk of preclinical failure and significant challenges in demonstrating superiority over established antibody therapies in a crowded market.
Competitive Landscape
Operates in the highly competitive antibody space, competing with large pharma and numerous biotechs, requiring a truly differentiated target or antibody construct.